MemoryPlus Israeli Company

MemoryPlus is pioneering an innovative treatment targeting Alzheimer’s-related cognitive decline, leveraging a novel mechanism of action (MOA). Its research is based on groundbreaking work from Prof. Shira Knafo, who discovered that the PTEN protein plays a critical role in memory decline by inhibiting neuronal activity. By disrupting the interaction between PTEN and PDZ domain proteins, the company has the potential to restore memory function.